Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.43 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 7/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389778 | 1.00 | TGFBR1 (0.43) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL25084816 | 0.89 | TGFBR1 (0.49) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL30156584 | 0.89 | TGFBR1 (0.49) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL30156066 | 0.81 | TGFBR1 (0.38) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL25084609 | 0.81 | TGFBR1 (0.38) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL25084528 | 0.76 | TGFBR1 (0.40) | TGFBR1TGFBR2MAP3K20CYP2D6 | |
| SCHEMBL30155826 | 0.76 | TGFBR1 (0.40) | TGFBR1TGFBR2MAP3K20CYP2D6 | |
| SCHEMBL25084820 | 0.76 | TGFBR1 (0.37) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL30156053 | 0.76 | TGFBR1 (0.37) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL23408256 | 0.76 | TGFBR1 (0.51) | TGFBR1TGFBR2MAP3K20CYP2D6THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4061809-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-114728941-A | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | TGFBR1 211/4885TGFBR2 290/4885MAP3K20 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.